February 5, 2018
Shire shares findings on lysosomal disease areas in San Diego
Shire said on Monday that it will have 12 presentations at the 14th annual WORLDSymposium 2018 in San Diego, in…
Pharmaceuticals, Biotechnology and Life Sciences
Category: Approval
February 5, 2018
Nymox plans submitting NDA for Fexapotide Triflutate, to treat BPH in US
Nymox Pharmaceutical will submit a New Drug Application (NDA) for Fexapotide Triflutate for the treatment of BPH in the US,…
February 3, 2018
Interview: Elena Piazza, Business Development and Marketing Manager at Bormioli Pharma
As a media partner for this year’s Pharmapack event in Paris, Pharmaceutical Daily has interviewed Elena Piazza, Business Development and…
February 3, 2018
Spang&Brands to showcase plastic primary packaging for pharmaceuticals
At Pharmapack in Paris, Spang & Brands is going to spotlight two innovative pharmaceutical devices: A single-use nasal dosing device…
February 2, 2018
FDA says “OK” to Allergan’s NDA for expanded use of hospital-acquired bacterial pneumonia AVYCAZ
Allergan’s supplemental New Drug Application (sNDA) to expand the approved use of AVYCAZ has gotten the FDA’s approval.
February 2, 2018
After total revenue declined 2% in the year, AstraZeneca positioned for product sales growth from FY 2018
AstraZeneca’s revenues improved over the course of the year, Pascal Soriot, Chief Executive Officer, commenting on the results said on…
February 2, 2018
Pacific Biosciences posts net loss for Q4 and year 2017
Pacific Biosciences of California said in its fourth quarter results announcement that it has had 19% of increase in product, service…
February 2, 2018
Gilead sciences welcomes new board member
Gilead Sciences has appointed new member to its board of directors, Jacqueline K. Barton who has previously served on Gilead’s Scientific…
February 2, 2018
Cardinal Health sells its China-based subsidiary to Shanghai Pharmaceuticals for $1.2 billion
Cardinal Health has disposed a business unit for $1.2 billion – its Cardinal Health China – to Shanghai Pharmaceuticals Holding.
February 2, 2018
Adler closes offering $250M of 2.50% Convertible Senior Notes Due 2025
A migraine treatment focused biopharmaceutical specialist, Alder BioPharmaceuticals, has closed on Thursday previously announced underwritten offering of $250 million aggregate…